Invisalign Itero

Press Release

Jul 24, 2019

Align Technology Announces Second Quarter 2019 Financial Results

Achieves 7 Millionth Invisalign Patient Milestone
  • Q2 revenues up 22.5% year-over-year to a record $600.7 million
  • Q2 Invisalign volume up 24.6% year-over-year to 377.1 thousand cases
  • Q2 scanner and services revenues up 82.4% year-over-year to $104.0 million
  • Q2 Invisalign cases for teenage patients up 32.2% year-over-year to 103.7 thousand
  • Q2 operating income of $176.5 million includes $51.0 million benefit from Straumann settlement
  • Q2 net profit of $147.1 million and $1.83 diluted EPS

SAN JOSE, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the second quarter ended June 30, 2019. Q2’19 Invisalign volume was 377.1 thousand cases, up 24.6% year-over-year. For the Americas and International regions, Q2’19 Invisalign volume was up 16.5% and 36.7% year-over-year, respectively. Q2’19 Invisalign volume for teenage patients was 103.7 thousand cases, up 32.2% year-over-year. Q2’19 total revenues were $600.7 million, up 22.5% year-over-year, and Q2’19 scanner and services revenues were $104.0 million, up 82.4% year-over-year.

Q2’19 operating income of $176.5 million was up 43.8% year-over-year resulting in an operating margin of 29.4%. Q2’19 net profit was $147.1 million, or $1.83 per diluted EPS. Q2’19 operating expense included a $51.0 million benefit from the ClearCorrect settlement with Straumann, which increased Q2 operating margin by approximately 8 points and benefited EPS by $0.57, respectively.

Commenting on Align’s second quarter results and outlook for the third quarter, Align Technology President and CEO Joe Hogan said, “Our second quarter revenues were at the high-end of our guidance, reflecting Invisalign volume growth primarily from international doctors, as well as very strong sales from iTero scanner and services. Q2 Invisalign volumes were up 24.6% year-over-year reflecting continued adoption from teenage and younger patients, as well as increased utilization among orthodontists and expansion of our customer base which totaled 60,000 active doctors worldwide. In Q2, total Invisalign case shipments were lower than expected, primarily due to a softness in China related to a tougher consumer environment and slower growth in young adult case in North America. Given the uncertainty in China, our outlook for the third quarter reflects a more cautious view for growth in the Asia Pacific region.”

GAAP Summary Financial Comparisons
Second Quarter Fiscal 2019

  Q2’19 Q1’19 Q2’18  Q/Q Change  Y/Y Change
Invisalign Case Shipments1  377,145  349,195  302,685  +8.0%  +24.6%
Net Revenues $600.7M $549.0M $490.3M  +9.4%  +22.5%
  Clear Aligner2 $496.7M $469.2M $433.3M  +5.9%  +14.6%
  Scanner & Services $104.0M $79.8M $57.0M  +30.4%  +82.4%
Net Profit3, 4 $147.1M $71.8M $106.1M  +104.8%  +38.7%
Diluted EPS3, 4 $1.83 $0.89 $1.30 +$0.94  +$0.53 

Note: Changes and percentages are based on actual values and may affect totals due to rounding
1 Invisalign shipment figures do not include SmileDirectClub aligners
2 Clear aligner revenue includes revenues from Invisalign clear aligners and SmileDirectClub aligners
3 Q1’19 results include impairments and other charges of $29.8 million related to closing Invisalign Stores as a result of the arbitrator’s decision regarding SmileDirectClub announced March 5, 2019.
4Q2’19 results include a $51.0 million gain from Straumann litigation settlement.

As of June 30, 2019, Align had $765.9 million in cash, cash equivalents and marketable securities compared to $732.5 million as of March 31, 2019. In May 2019, we purchased on the open market approximately 0.2 million shares of our common stock at an average price of $307.48 per share, including commission, for an aggregate purchase price of $49.5 million. We have $400.5 million remaining available for repurchase under the May 2018 Repurchase Program.     

Announcements and Highlights

The following list highlights Align’s key announcements over the past quarter:

  • During the quarter, Align shipped its 7 millionth Invisalign patient who is a young child in the U.S. being treated with Invisalign First.
  • Announced that Align and Straumann Group terminated discussions concerning a possible development and distribution agreement that was disclosed as part of the patent settlement agreement announced by the two companies in March of this year.  
  • Announced that Simon Beard was appointed as senior vice president of the Americas region and Markus Sebastian was promoted to senior vice president of the EMEA region. 
  • Align awarded ten research grants totaling $250,000 as part of its ongoing annual research awards program to universities worldwide. 
  • Announced that Roger E. George, Align senior vice president, chief legal and regulatory officer has retired and that Julie Coletti was appointed to senior vice president and Chief Legal and Regulatory Officer.  
  • Announced that on April 26, 2019, an Administrative Law Judge with the United States International Trade Commission issued an Initial Determination regarding her investigation of 3Shape’s infringement on Align’s patents.
  • Align completed the purchase of the Raleigh office building located in Morrisville, NC. This office serves as the Americas headquarters.

Invisalign and iTero Intraoral Scanner

  • Launched the new iTero Element Foundation intraoral scanner with restorative software. The iTero Element Foundation extends Align’s portfolio of intraoral scanners with powerful 3D visualization to better meet the needs of doctors, labs and patients.

Q3 2019 Business Outlook

For the third quarter of 2019 (Q3’19), Align provides the following guidance:

  • Net revenues in the range of $585 million to $600 million, up approximately 16% to 19% over the same period a year ago
  • Invisalign case shipments in the range of 370 thousand to 380 thousand, up approximately 16% to 19% over the same period a year ago
  • Operating margin in the range of 19.8% to 20.5%
  • Diluted EPS in the range of $1.09 to $1.16
  • In addition, we expect to repurchase at least $100 million of our stock in the open market in Q3
  • As we continue our operational expansion efforts, we expect CapEx for Q3 to be approximately $50 million to $55 million, and we expect depreciation and amortization to be $24 million to 26 million

Align Web Cast and Conference Call
Align will host a conference call today, July 24, 2019 at 4:30 p.m. ET, 1:30 p.m. PT, to review its second quarter 2019 results, discuss future operating trends and the business outlook. The conference call will also be web cast live via the Internet. To access the webcast, go to the “Events & Presentations” section under Company Information on Align’s Investor Relations web site at To access the conference call, please dial 201-689-8261. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 13691835 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on August 7, 2019.

About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit For additional information about iTero digital scanning system, please visit

Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the third quarter of 2019, including, but not limited to, anticipated net revenues, gross margin, operating expenses, operating profit, capital expenditures, depreciation and amortization, diluted earnings per share, tax rate, case shipments, and our expectations regarding stock repurchases during the quarter. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, including Align’s predictions related to a tougher consumer demand environment in China, especially for U.S. based products and services, Align’s expectations regarding the continued growth of our international markets, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, Align’s expectations regarding the sales growth of its intra-oral scanner sales in international markets, its belief that technology features and functionality of the iTero scanners will increase adoption of Invisalign and increase sales of Align’s intra-oral scanners, Align’s expectations regarding the financial and strategic benefits of establishing regional order acquisition, treatment planning and manufacturing facilities, the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated, Align’s expectation to incur additional costs related to the planned corporate structure reorganization, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, the expected impact additional sales representatives will have on our sales in 2019, growth related risks, including excess or constrained capacity at our manufacturing and treat operations facilities and pressure on our internal systems and personnel, the security of customer and/or patient data is compromised for any reason, system integration and implementation issues, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter as well as an increased manufacturing costs per case, acceptance of our products by consumers and dental professionals, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to develop and successfully introduce new products and product enhancements and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2019 and its latest Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, which was filed with the SEC on May 2, 2019. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(in thousands, except per share data) 
  Three Months Ended
June 30,
  Six Month Ended
June 30,
Net revenues $    600,697     $   490,259     $    1,149,668     $    927,183  
Cost of net revenues      168,408         124,677         315,283         234,193  
Gross profit     432,289         365,582         834,385         692,990  
Operating expenses:                              
Selling, general and administrative     267,948         212,087         515,058         411,712  
Research and development     38,851         30,804         76,354         60,395  
Impairments and other charges     -          -          29,782         -   
Litigation settlement gain     (51,000       -          (51,000       -   
Total operating expenses     255,799         242,891         570,194         472,107  
Income from operations     176,490         122,691         264,191         220,883  
Interest income     3,465         1,917         6,098         4,093  
Other income (expense), net     13,892         (7,099       8,146         (6,922 )
Net income before provision for income taxes and equity in losses of investee     193,847         117,509         278,435         218,054  
Provision for income taxes     43,121         7,703         51,917         10,605  
Equity in losses of investee, net of tax     3,584         3,701         7,528         5,478  
Net income $    147,142     $    106,105     $    218,990     $    201,971  
Net income per share:                              
Basic $   1.84     $    1.32     $    2.74     $    2.52  
Diluted $    1.83     $   1.30     $    2.71     $    2.48  
Shares used in computing net income per share:                              
Basic     79,943         80,216         79,901         80,127  
Diluted     80,590         81,471         80,665         81,575  


(in thousands) 
   June 30,
  December 31,
Current assets:          
Cash and cash equivalents $    423,500   $    636,899
Marketable securities, short-term     297,422       98,460
Accounts receivable, net     520,094       439,009
Inventories     81,124       55,641
Prepaid expenses and other current assets     135,234       72,470
Total current assets     1,457,374       1,302,479
Marketable securities, long-term     44,969       9,112
Property, plant and equipment, net     599,611       521,329
Operating lease right-of-use assets     57,269       - 
Equity method investments     -        45,913
Goodwill and intangible assets, net     78,852       81,949
Deferred tax assets     59,050       64,689
Other assets     48,892       26,987
Total assets $    2,346,017   $   2,052,458
Current liabilities:          
Accounts payable $    61,950   $    64,256
Accrued liabilities     245,634       234,679
Deferred revenues     481,462       393,138
Total current liabilities     789,046       692,073
Income tax payable     98,182       78,008
Operating lease liabilities     59,140       - 
Other long-term liabilities     25,967       29,486
Total liabilities      972,335       799,567
Total stockholders' equity     1,373,682       1,252,891
Total liabilities and stockholders' equity  $    2,346,017   $    2,052,458


(in thousands) 
  Six Months Ended
June 30,
Net cash provided by operating activities $   294,561     $   217,121  
Net cash (used in) provided by investing activities     (321,020       54,003  
Net cash used in financing activities     (188,381       (170,745 )
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash     1,467         (1,923 )
Net (decrease) increase in cash, cash equivalents, and restricted cash     (213,373       98,456  
Cash, cash equivalents, and restricted cash at beginning of the period     637,566         450,125  
Cash, cash equivalents, and restricted cash at end of the period $    424,193     $    548,581  


Invisalign Average Selling Price (ASP):                                        
Worldwide ASP  $    1,310      1,315   $    1,230   $    1,235   $    1,270   $    1,245   $    1,230
International ASP $    1,435   $    1,425   $    1,340   $    1,295   $    1,370   $    1,330   $    1,305
Invisalign Cases Shipped by Geography:                                        
Americas   166,665     181,425     190,615     189,410     728,115     202,935     211,360
International   105,570     121,260     128,730     144,390     499,950     146,260     165,785
Total Cases Shipped   272,235     302,685     319,345     333,800     1,228,065     349,195     377,145
 YoY % growth   30.8%     30.5%     35.3%     30.9%     31.9%     28.3%     24.6%
 QoQ % growth   6.7%     11.2%     5.5%     4.5%           4.6%     8.0%
Number of Invisalign Doctors Cases Were Shipped To:                                    
Americas   27,105     28,280     28,890     29,215     42,000     30,200     31,445
International   19,700     21,805     23,270     25,475     36,040     26,510     28,970
Total Doctors Cases Shipped To   46,805     50,085     52,160     54,690     78,040     56,710     60,415
Invisalign Doctor Utilization Rates**:                                        
North America    6.3     6.6     6.9     6.7     18.2     7.0     7.0
North American Orthodontists    15.3     16.4     17.4     16.5     56.7     18.3     18.9
North American GP Dentists    3.4     3.6     3.5     3.6     9.1     3.6     3.6
International   5.4     5.6     5.5     5.7     13.9     5.5     5.7
Total Utilization Rates   5.8     6.0     6.1     6.1       15.7       6.2       6.2
Number of Invisalign Doctors Trained***:                                        
Americas   1,630     1,880       2,085       2,290     7,885     1,725     2,890
International     2,645       3,300       2,845       2,980     11,770     2,410     3,520
Total Doctors Trained Worldwide   4,275     5,180     4,930     5,270     19,655     4,135     6,410
Total to Date Worldwide   136,575     141,755     146,685     151,955   151,955     156,090     162,500
Note: Historical public data may differ due to rounding. Additionally, rounding may effect totals. Effective Q1'18, Americas region includes North America and LATAM. International region includes EMEA and APAC. We have recasted historical data to reflect the change.
* Invisalign business metrics exclude SmileDirectClub aligners.       
** # of cases shipped / # of doctors to whom cases were shipped. LATAM utilization rate is not separately disclosed, but included in the total utilization rates. 
***2018 adjusted to reflect Americas doctors trained for Invisalign iGo 


ALIGN TECHNOLOGY, INC.               
(in thousands)                                        
Stock-based Compensation (SBC)                                        
SBC included in Gross Profit $    881   $    900   $    966   $    948   $    3,695   $    1,112   $    1,278
SBC included in Operating Expenses   14,949     15,990     18,232     17,897     67,068     19,932     21,189
Total SBC Expense $    15,830   $    16,890   $    19,198   $    18,845   $    70,763   $    21,044   $    22,467


The outlook figures provided below and elsewhere in this press release are approximate in nature since Align’s business outlook is difficult to predict.  Align’s future performance involves numerous risks and uncertainties and the company’s results could differ materially from the outlook provided.  Some of the factors that could affect Align’s future financial performance and business outlook are set forth under “Forward Looking Information” above in this press release. 
Financial Outlook      
(in millions, except per share amounts and percentages)  
    Q3'19 Guidance  
Net Revenues   $585M - $600M  
Gross Margin   71.9% - 72.5%  
Operating Expenses   $305M - $312M  
Operating Margin   19.8% - 20.5%  
Net Income per Diluted Share   $1.09 - $1.16  
Business Metrics:   Q3'19  
Case Shipments   370K - 380K  
Capital Expenditure   $50M-$55M  
Depreciation & Amortization   $24M-$26M  
Diluted Shares Outstanding   80.6M (1)
Stock Based Compensation Expense   $25.0M  
Effective Tax Rate   ~24% (2)
(1) Excludes any stock repurchases during the quarter
(2) Includes excess tax benefits related to share-based compensation expense pursuant to ASU 2016-09  


Align Technology:     Zeno Group:
Madelyn Homick     Sarah Johnson
(408) 470-1180     (828) 551-4201



Source: Align Technology, Inc.


Data Provided by Refinitiv. Minimum 15 minutes delayed.